PURPOSE: To determine the effect of estrogen replacement therapy (ERT) on recurrence rate and survival in women who have undergone surgery for stage I or II endometrial cancer. PATIENTS AND METHODS: After surgery, eligible patients were allocated to therapy with ERT or placebo after undergoing hysterectomy with or without pelvic and aortic nodal sampling. Planned duration of hormonal versus placebo treatment was 3 years, with an additional 2 years of follow-up. RESULTS: The median follow-up time for all 1,236 eligible and assessable patients was 35.7 months. Stage, grade, histologic subtype, and percentage of patients receiving adjuvant therapy were similarly distributed between the groups. The median age at diagnosis for the 618 patients randomly assigned to ERT was 57 years (range, 26 to 91 years). Two hundred fifty-one patients (41.1%) were compliant with ERT for the entire treatment period. Disease recurrence was experienced in 14 patients (2.3%). Eight patients (1.3%) developed a new malignancy. There were 26 deaths (4.2%), and five deaths (0.8%) were a result of endometrial cancer. The median age at diagnosis for the 618 patients in the placebo group was 57 years (range, 30 to 88 years). Twelve patients (1.9%) experienced disease recurrence. Ten patients (1.6%) developed a new malignancy. There were 9 deaths (3.1%) in the placebo group, and four deaths (0.6%) were a result of endometrial cancer. CONCLUSION: Although this incomplete study cannot conclusively refute or support the safety of exogenous estrogen with regard to risk of endometrial recurrence, it is noteworthy that the absolute recurrence rate (2.1%) and the incidence of new malignancy were low.
RCT Entities:
PURPOSE: To determine the effect of estrogen replacement therapy (ERT) on recurrence rate and survival in women who have undergone surgery for stage I or II endometrial cancer. PATIENTS AND METHODS: After surgery, eligible patients were allocated to therapy with ERT or placebo after undergoing hysterectomy with or without pelvic and aortic nodal sampling. Planned duration of hormonal versus placebo treatment was 3 years, with an additional 2 years of follow-up. RESULTS: The median follow-up time for all 1,236 eligible and assessable patients was 35.7 months. Stage, grade, histologic subtype, and percentage of patients receiving adjuvant therapy were similarly distributed between the groups. The median age at diagnosis for the 618 patients randomly assigned to ERT was 57 years (range, 26 to 91 years). Two hundred fifty-one patients (41.1%) were compliant with ERT for the entire treatment period. Disease recurrence was experienced in 14 patients (2.3%). Eight patients (1.3%) developed a new malignancy. There were 26 deaths (4.2%), and five deaths (0.8%) were a result of endometrial cancer. The median age at diagnosis for the 618 patients in the placebo group was 57 years (range, 30 to 88 years). Twelve patients (1.9%) experienced disease recurrence. Ten patients (1.6%) developed a new malignancy. There were 9 deaths (3.1%) in the placebo group, and four deaths (0.6%) were a result of endometrial cancer. CONCLUSION: Although this incomplete study cannot conclusively refute or support the safety of exogenous estrogen with regard to risk of endometrial recurrence, it is noteworthy that the absolute recurrence rate (2.1%) and the incidence of new malignancy were low.
Authors: Sakthivel Muniyan; Yu-Wei Chou; Te-Jung Tsai; Paul Thomes; Suresh Veeramani; Benedict B Benigno; L DeEtte Walker; John F McDonald; Shafiq A Khan; Fen-Fen Lin; Subodh M Lele; Ming-Fong Lin Journal: Mol Carcinog Date: 2014-01-07 Impact factor: 4.784
Authors: Koji Matsuo; James C Cripe; Katherine C Kurnit; Michiko Kaneda; Audrey S Garneau; Gretchen E Glaser; Aaron Nizam; Rachel M Schillinger; Michelle L Kuznicki; Akira Yabuno; Shiori Yanai; Denise M Garofalo; Jiro Suzuki; Jessica D St Laurent; Ting-Tai Yen; Annie Y Liu; Masako Shida; Mamoru Kakuda; Tetsuro Oishi; Shin Nishio; Jenna Z Marcus; Sosuke Adachi; Tetsuji Kurokawa; Malcolm S Ross; Max P Horowitz; Marian S Johnson; Min K Kim; Alexander Melamed; Karime K Machado; Kosuke Yoshihara; Yoshio Yoshida; Takayuki Enomoto; Kimio Ushijima; Shinya Satoh; Yutaka Ueda; Mikio Mikami; Bobbie J Rimel; Rebecca L Stone; Whitfield B Growdon; Aikou Okamoto; Saketh R Guntupalli; Kosei Hasegawa; Mian M K Shahzad; Dwight D Im; Marina Frimer; Bobbie S Gostout; Frederick R Ueland; Shoji Nagao; Pamela T Soliman; Premal H Thaker; Jason D Wright; Lynda D Roman Journal: Gynecol Oncol Date: 2019-08-16 Impact factor: 5.482
Authors: Wulf H Utian; David F Archer; Gloria A Bachmann; Christopher Gallagher; Francine n Grodstein; Julia R Heiman; Victor W Henderson; Howard N Hodis; Richard H Karas; Rogerio A Lobo; JoAnn E Manson; Robert L Reid; Peter J Schmidt; Cynthia A Stuenkel Journal: Menopause Date: 2008 Jul-Aug Impact factor: 2.953
Authors: Koji Matsuo; Marc R Gualtieri; Sigita S Cahoon; Carrie E Jung; Richard J Paulson; Donna Shoupe; Laila I Muderspach; Akihiko Wakatsuki; Jason D Wright; Lynda D Roman Journal: Menopause Date: 2016-02 Impact factor: 2.953